Trial Profile
Receptor radionuclide therapy with [177Lu-DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2021
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours
- Focus Therapeutic Use
- 22 Mar 2017 New trial record